Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Shire plc, a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in Ireland (IE) and operates extensively across Europe, North America, and Asia. Founded in 1986, Shire has established itself as a leader in developing innovative therapies for rare diseases and complex conditions, focusing on areas such as neuroscience, immunology, and genetic disorders.
The company is renowned for its unique portfolio of products, including treatments for attention deficit hyperactivity disorder (ADHD) and rare genetic disorders, which set it apart in a competitive market. Shire's commitment to research and development has led to significant milestones, including numerous FDA approvals and a strong market position, making it a trusted name in the pharmaceutical sector. With a dedication to improving patient outcomes, Shire continues to advance its mission of transforming the lives of those with challenging health conditions.
+18 vs industry average
Shire plc’s score of 60 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Shire plc, a pharmaceutical preparation manufacturing company headquartered in Ireland, reported its most recent carbon emissions for 2016. In that year, the company's Scope 1 emissions were approximately 26.2 million kg CO2e, and its Scope 2 emissions were approximately 118 million kg CO2e. Scope 3 emissions were reported as approximately 34.1 million kg CO2e. Shire plc's emissions data is reported directly by the organisation.
No specific carbon reduction targets or commitments, such as those verified by the Science Based Targets initiative (SBTi), are directly attributable to Shire plc. However, relevant SBTi targets are cascaded from its ultimate parent, Takeda Pharmaceutical Company Limited, through a corporate family relationship. Similarly, information regarding membership in the RE100 and Race to Zero (RTZ) initiatives also cascades from Takeda Pharmaceutical Company Limited.
No climate goals have been disclosed for Shire plc yet.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more